Comparison of growth-inhibitory agents by fluorescence imaging of human skin re-epithelialization in vitro

Acta Dermato-Venereologica

Volumn 86, Issue 4, 2006, Pages 292-299

  Forsberg, Sofi ^a   Saarialho Kere, Ulpu ^b,c   Rollman, Ola ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Epidermal growth factor; Epidermis; Fluorescent tracer; Proliferation; Tyrosine kinase inhibitors

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTIPSORIASIS AGENT; BETAMETHASONE; CALCIPOTRIOL; DITHRANOL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GROWTH INHIBITOR; KALININ; TACROLIMUS; TAZAROTENE;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG MECHANISM; EPIDERMIS; EPITHELIZATION; EXPLANT; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KERATINOCYTE; MORPHOMETRICS; PAPILLOMATOSIS; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; TISSUE CULTURE;

APOPTOSIS; CELL ADHESION MOLECULES; CELL MOVEMENT; CELL PROLIFERATION; DERMATOLOGIC AGENTS; DRUG EVALUATION, PRECLINICAL; EPIDERMIS; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MICROSCOPY, FLUORESCENCE; PSORIASIS; SKIN;

EID: 33746520000     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0089     Document Type: Article

References (50)

1. Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. The human epidermis models EpiSkin®, SkinEthic® and EpiDerm®: An evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur J Pharm Biopharm 2005; 60: 167-178.
2. Coulomb B, Saiag P, Bell E, Breitburd F, Lebreton C, Heslan M, et al. A new method for studying epidermalization in vitro. Br J Dermatol 1986; 114: 91-101.
3. Regnier M, Asselineau D, Lenoir MC. Human epidermis reconstructed on dermal substrates in vitro: an alternative to animals in skin pharmacology. Skin Pharmacol 1990; 3: 70-85.
4. Lu H, Rollman O. Fluorescence imaging of reepithelialization from skin explant cultures on acellular dermis. Wound Repair Regen 2004; 12: 575-586.
5. Rikimaru K, Moles JP, Watt FM. Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture. Exp Dermatol 1997; 6: 214-221.
6. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y. Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 1994; 211: 314-321.
7. Johnson I. Fluorescent probes for living cells. Histochem J 1998; 30: 123-140.
8. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225-231.
9. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, et al. The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994; 145: 782-791.
10. Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, et al. Differential expression of matrilysin-1 (MMP-7), 92 RD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004; 202: 14-22.
11. Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. New York: Springer, 2000.
12. Larjava H, Salo T, Haapasalmi K, Kramer RH, Heino J. Expression of integrins and basement membrane components by wound keratinocytes. J Clin Invest 1993; 92: 1425-1435.
13. Mirastschijski U, Bugdahl R, Rollman O, Johansson BR, Ågren MS. Epithelial regeneration from bioengineered skin explants in culture. Br J Dermatol 2006; 154: 42-49.
14. Chakrabarty KH, Heaton M, Dalley AJ, Dawson RA, Freedlander E, Khaw PT, et al. Keratinocyte-driven contraction of reconstructed human skin. Wound Repair Regen 2001; 9: 95-106.
15. Lee DY, Ahn HT, Cho KH. A new skin equivalent model: dermal substrate that combines de-epidermized dermis with fibroblast-populated collagen matrix. J Dermatol Sci 2000; 23: 132-137.
16. Regnier M, Prunieras M, Woodley D. Growth and differentiation of adult human epidermal cells on dermal substrates. Front Matrix Biol 1981; 9: 4-35.
17. Basset-Seguin N, Culard JF, Kerai C, Bernard F, Watrin A, Demaille J, et al. Reconstituted skin in culture: a simple method with optimal differentiation. Differentiation 1990; 44: 232-238.
18. Zhang K, Kramer RH. Laminin 5 deposition promotes keratinocyte motility. Exp Cell Res 1996; 227: 309-322.
19. Nishiyama T, Amano S, Tsunenaga M, Kadoya K, Takeda A, Adachi E, et al. The importance of laminin 5 in the dermal-epidermal basement membrane. J Dermatol Sci 2000; 24 (suppl 1): S51-59.
20. Mahrle G. Dithranol. Clin Dermatol 1997; 15: 723-737.
21. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris. Cutis 1990; 46: 341-350.
22. van de Kerkhof PC. The topical treatment of psoriasis. Clin Exp Dermatol 2005; 30: 205-208.
23. Kragballe K. Vitamin D analogues in the treatment of psoriasis. J Cell Biochem 1992; 49: 46-52.
24. De Tran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg 2001; 5: 329-335.
25. Roeder A, Schaller M, Schafer-Korting M, Korting HC. Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol 2004; 17: 111-118.
26. Pol A, Bergers M, Schalkwijk J. Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay. In Vitro Cell Dev Biol Anim 2003; 39: 36-42.
27. Wach F, Bosserhoff A, Kurzidym U, Nowok K, Landthaler M, Hein R. Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998; 11: 43-51.
28. Lee E, Jeon SH, Yi JY, Jin YJ, Son YS. Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun 2001; 284: 419-425.
29. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci 1996; 12: 246-254.
30. Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997; 37: S18-24.
31. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003; 7: 215-234.
32. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499-512.
33. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004; 13: 106-112.
34. Reichrath J, Muller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
35. Saarialho-Kere U, Kerkela E, Jahkola T, Suomela S, Keski-Oja J, Lohi J. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol 2002; 119: 14-21.
36. Hudson LG, McCawley LJ. Contributions of the epidermal growth factor receptor to keratinocyte motility. Microsc Res Tech 1998; 43: 444-455.
37. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-510.
38. Piepkorn M, Pittelkow MR, Cook PW. Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998; 111: 715-721.
39. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742-748.
40. Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005; 25: 1205-1210.
41. Krahn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer 2001; 37: 251-259.
42. Nanney LB, Stoscheck CM, Magid M, King LE Jr. Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986; 86: 260-265.
43. Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, Gemmell L, et al. Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 2005; 166: 1009-1016.
44. Varani J, Kang S, Stoll S, Elder JT. Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998; 66: 253-259.
45. Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCollough J, et al. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999; 141: 802-810.
46. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 (suppl 4): 2-8.
47. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
48. Peus D, Harnacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 1997; 109: 751-756.
49. Tavakkol A, Varani J, Elder JT, Zouboulis CC. Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor. Arch Dermatol Res 1999; 291: 643-651.
50. Varani J, Lateef H, Fay K, Elder JT. Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin. Skin Pharmacol Physiol 2005; 18: 123-131.